Study of transplant preparation for older adults with AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special preparation (conditioning) regimen for patients 55 or older with acute myeloid leukemia (AML) who are in first remission and receiving a half-matched (haploidentical) stem cell transplant. It aims to make the transplant safer and more effective for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years old or older.
- You have been diagnosed with acute myeloid leukemia (AML) and are in your first complete remission (meaning the leukemia is not active right now).
- You have a half-matched (haploidentical) donor available, such as a parent, child, or sibling.
- This would be your first stem cell transplant.
- You do not have a fully matched sibling or unrelated donor available.
- You are willing to give written permission to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial studies a gentler (“micro-”) transplant approach for people ages 60–74 with acute myeloid leukemia (AML) who are in remission and cannot safely have the usual stronger transplant conditioning. It may help reduce transplant risks while keeping the leukemia under control.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.